Skip to search formSkip to main contentSkip to account menu
You are currently offline. Some features of the site may not work correctly.

posaconazole

Known as: posaconazole [Chemical/Ingredient] 
A broad-spectrum, second generation, triazole compound with antifungal activity. Posaconazole strongly inhibits 14-alpha demethylase, a cytochrome… Expand
National Institutes of Health

Related topics

Related topics

15 relations

Broader (4)

14-alpha Demethylase InhibitorsAntifungal AgentsTriazolesTrypanocidal Agents
16.7 ML posaconazole 18 MG/ML Injection [Noxafil]AzolesMycosesPosaconazole:MCnc:Pt:Ser/Plas:Qn
Expand

Narrower (2)

NoxafilSCH-56592

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2014
Highly Cited
2014
Randomized trial of posaconazole and benznidazole for chronic Chagas' disease.
BACKGROUND Current therapeutic options for Chagas' disease are limited to benznidazole and nifurtimox, which have been associated… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Highly Cited
2009
Highly Cited
2009
Frequency and Evolution of Azole Resistance in Aspergillus fumigatus Associated with Treatment Failure1
An increase in the frequency of azole-resistant Aspergillus fumigatus has emerged. 
  • table 1
  • figure 1
  • table 2
  • table 3
  • figure 2
Highly Cited
2007
Highly Cited
2007
Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.
BACKGROUND Patients with neutropenia resulting from chemotherapy for acute myelogenous leukemia or the myelodysplastic syndrome… Expand
  • table 1
  • table 1
  • figure 1
  • table 2
  • table 3
Highly Cited
2007
Highly Cited
2007
Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease.
BACKGROUND Invasive fungal infections are an important cause of morbidity and mortality after allogeneic hematopoietic stem-cell… Expand
Review
2007
Review
2007
Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial.
BACKGROUND Invasive aspergillosis is an important cause of morbidity and mortality in immunocompromised patients. Current… Expand
Highly Cited
2006
Highly Cited
2006
Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases.
To evaluate the activity of posaconazole for treatment of zygomycosis, a disease for which therapeutic options are limited, we… Expand
  • table 1
Highly Cited
2006
Highly Cited
2006
Posaconazole as Salvage Therapy for Zygomycosis
ABSTRACT Zygomycosis, an infection that is associated with significant morbidity and mortality, is becoming common in… Expand
Highly Cited
2006
Highly Cited
2006
Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions.
BACKGROUND Conventional amphotericin B-based antifungal therapy for invasive fusariosis in patients with a hematologic malignancy… Expand
  • table 1
  • table 2
Highly Cited
2006
Highly Cited
2006
In Vitro Activities of Posaconazole, Fluconazole, Itraconazole, Voriconazole, and Amphotericin B against a Large Collection of Clinically Important Molds and Yeasts
ABSTRACT The in vitro activity of the novel triazole antifungal agent posaconazole (Noxafil; SCH 56592) was assessed in 45… Expand
Highly Cited
2004
Highly Cited
2004
Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults.
AIMS This randomized, crossover, single-dose study evaluated the relative oral bioavailability of posaconazole suspension and… Expand
  • figure 1
  • table 1
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE